Prevention of Diseases Induced by Chlamydia Trachomatis

Status: Active, not recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The main objective of the study is to determine whether early screening and treating young women (<25 years of age) for genital Chlamydia Trachomatis (Ct) infection reduces the cumulative incidence of pelvic inflammatory disease (PID) over 24 months. As secondary objectives, the study aims To determine the baseline prevalence and the incidence of Ct infection; To improve knowledge on natural history of Ct infection in young women such as the rate and timing of progression to PID (at the beginning of the infection, at the end, throughout the course of infection), as well as the incidence of reinfections with Ct; To investigate the relation between host immuno-genetic factors and the clearance, persistence and development of late complications (PID) as an explanation for the inter-individual heterogeneity in the susceptibility to and course of Ct infection.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 24
Healthy Volunteers: Accepts Healthy Volunteers
View:

• female students visiting the preventive medical centers of universities or the Ct screening test centers who participate in the study;

• participate in or will participate in the i-Share cohort;

• aged between 18 to 24 years,

• had prior sexual relations,

• written informed consent signed,

• affiliated to the social security bodies.

Locations
Other Locations
France
Université de Versailles Saint Quentin
Versailles
Time Frame
Start Date: January 10, 2017
Estimated Completion Date: July 2022
Participants
Target number of participants: 2728
Treatments
Experimental: Intervention group
Testing for Ct infection immediately~Participants will perform self-taken vaginal samples.~The positive results for Ct will be examined and treated and their partner will also be informed to do so.
Experimental: Control group
Testing for Ct infection at the end of the study
Related Therapeutic Areas
Sponsors
Collaborators: National Reference Center (NRC) for Chlamydia infections, UMR1181
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov

Similar Clinical Trials